Astellas have strengthened their ophthalmic gene therapy programme through the acquisition of Quethera, who focus on the development of treatments for ocular disorders including glaucoma.
President and chief executive of Astellas Kenji Yasukawa said “This acquisition demonstrates our commitment to incorporating scientific and technological advances, and turning them into value for our patients.”
“Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma.“
Quethers chief executive Peter Widdowson said “This deal enables us to accelerate the programme and see if we can slow down or prevent disease progression for patients.”
Once closed, Quethera will become a subsidiary of Astellas.